Investment Thesis
RGNX exhibits severe financial distress with $90.1M net losses against $6.4M revenue and unsustainable -$77.4M free cash flow burn. With only $15.2M cash and $320.8M liabilities against $21.1M stockholders' equity, the company faces critical liquidity risk and requires immediate capital infusion to survive. Without demonstrable revenue growth or near-term commercialization success, fundamental viability is highly questionable.
Strengths
- Current ratio of 2.62x provides short-term liquidity buffer
- No long-term debt burden reducing servicing obligations
- Net loss improved 14.6% YoY indicating marginal operational progress
Risks
- Catastrophic burn rate of -$77.4M free cash flow against $15.2M cash reserves (~2 months runway)
- Stockholders' equity depleted to $21.1M with $320.8M total liabilities indicating structural insolvency risk
- Zero revenue growth (0.0% YoY) with revenue of only $6.4M inadequate to support R&D stage company
- Negative equity returns (-427.1% ROE) destroying shareholder value at unsustainable rate
- Minimal insider buying activity (2 Form 4s/90 days) suggests low confidence from management
Key Metrics to Watch
- Cash runway and next funding event timeline
- Pipeline milestone achievements and clinical trial progression
- Monthly operating burn rate trend and cash position changes
- Revenue growth inflection or product commercialization progress
Financial Metrics
Revenue
6.4M
Net Income
-90.1M
EPS (Diluted)
$-1.72
Free Cash Flow
-77.4M
Total Assets
341.9M
Cash
15.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,304.0%
Net Margin
-1,408.6%
ROE
-427.1%
ROA
-26.3%
FCF Margin
-1,211.0%
Balance Sheet & Liquidity
Current Ratio
2.62x
Quick Ratio
2.62x
Debt/Equity
0.00x
Debt/Assets
93.8%
Interest Coverage
-34.42x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T07:51:22.669853 |
Data as of: 2026-03-31 |
Powered by Claude AI